Effects of HBO Therapy on Muscular Insulin Resistence in Type 2 Diabetes
1 other identifier
interventional
30
1 country
1
Brief Summary
Hyperbaric oxygen therapy (HBO) is applied for several diseases. The effect on insulin sensitivity is yet unknown. Hypothesis: HBO therapy improves insulin sensitivity in patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable obesity
Started Mar 2012
Typical duration for not_applicable obesity
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 13, 2011
CompletedFirst Posted
Study publicly available on registry
November 16, 2011
CompletedStudy Start
First participant enrolled
March 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2015
CompletedJune 13, 2023
June 1, 2023
3 years
November 13, 2011
June 11, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Skeletal muscle insulin sensitivity
Determination of the influence of 2 hours hyperoxygenation on insulin sensitivity redox balance and lipid metabolites of skeletal muscle in patients with T2DM
2 years
Study Arms (2)
Hyperbaric oxygen therapy
EXPERIMENTALEffect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
Hyperbaric room air
SHAM COMPARATOREffect of 2 hrs hyperbaric room air herapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
Interventions
Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
Eligibility Criteria
You may qualify if:
- Aged ≥ 30 years- ≤ 70 years
- Balanced sex (50: 50)
- BMI 20- 25 kg/m 2 normal- weight group
- BMI 35- 39,9 kg/m 2 (Obese typ II)
You may not qualify if:
- Acute illness 2 weeks before start of examination
- Autoimmune or Immune disorder deseases (Leukozyten \< 5000/µl
- Renal insufficiency (Kreatin \> 1,5 mg/dl)
- Heart disease, condition after heart attack
- Anemia (Hb \<12g/l, contolled before every day of eximination) or blood donations 4weeks before eximinatin.
- Participation in another trial within the last 2 weeks
- Pharmacological- immuno therapy (Cortisol, Antihistaminika, ASS)
- Thyroid disorders
- Glitazone or Insulin- Therapy
- Pragnancy, Lactation, Menstruation
- Smoking cigaretts, Alcohol- and drug abuse
- Psychiatric disorders
- Risk for/ or diagnosed HIV/ AIDS or Hepatitis B/C
- Liver disease, which are not caused by non- alcoholic steato- hepatitis
- Working on night shifts or irregular rhythem of night- day
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- German Diabetes Centerlead
- Heinrich-Heine University, Duesseldorfcollaborator
Study Sites (1)
German Diabetes Center
Düsseldorf, 40225, Germany
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael Roden, Prof., MD
German Diabetes Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 13, 2011
First Posted
November 16, 2011
Study Start
March 1, 2012
Primary Completion
March 1, 2015
Study Completion
August 1, 2015
Last Updated
June 13, 2023
Record last verified: 2023-06